PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
22.84%
Some net income increase while AVXL is negative at -17.07%. John Neff would see a short-term edge over the struggling competitor.
7.12%
D&A growth of 7.12% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-26.57%
Negative yoy SBC while AVXL is 9.24%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-21.66%
Negative yoy working capital usage while AVXL is 203.28%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy AP while AVXL is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
161.21%
Growth well above AVXL's 203.28%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
200.00%
Well above AVXL's 178.67%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
22.87%
Operating cash flow growth similar to AVXL's 22.08%. Walter Schloss would see parallel improvements or market conditions in cash generation.
-183.51%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-183.51%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-107.12%
Both yoy lines negative, with AVXL at -89.13%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.